420 related articles for article (PubMed ID: 32561716)
21. Analysis of direct repeats and spacers of CRISPR/Cas systems type I-F in Brazilian clinical strains of Pseudomonas aeruginosa.
Luz ACO; da Silva JMA; Rezende AM; de Barros MPS; Leal-Balbino TC
Mol Genet Genomics; 2019 Oct; 294(5):1095-1105. PubMed ID: 31098740
[TBL] [Abstract][Full Text] [Related]
22. Rational designs of in vivo CRISPR-Cas delivery systems.
Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
[TBL] [Abstract][Full Text] [Related]
23. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
[TBL] [Abstract][Full Text] [Related]
24. The CRISPR-Cas toolbox and gene editing technologies.
Liu G; Lin Q; Jin S; Gao C
Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414
[TBL] [Abstract][Full Text] [Related]
25. Chemical control of CRISPR/Cpf1 editing
Lin CL; Chen WD; Liu L; Cheng L
Chem Commun (Camb); 2024 May; 60(39):5197-5200. PubMed ID: 38651297
[TBL] [Abstract][Full Text] [Related]
26. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.
Zetsche B; Heidenreich M; Mohanraju P; Fedorova I; Kneppers J; DeGennaro EM; Winblad N; Choudhury SR; Abudayyeh OO; Gootenberg JS; Wu WY; Scott DA; Severinov K; van der Oost J; Zhang F
Nat Biotechnol; 2017 Jan; 35(1):31-34. PubMed ID: 27918548
[TBL] [Abstract][Full Text] [Related]
27. A compact Cascade-Cas3 system for targeted genome engineering.
Csörgő B; León LM; Chau-Ly IJ; Vasquez-Rifo A; Berry JD; Mahendra C; Crawford ED; Lewis JD; Bondy-Denomy J
Nat Methods; 2020 Dec; 17(12):1183-1190. PubMed ID: 33077967
[TBL] [Abstract][Full Text] [Related]
28. Anti-CRISPR proteins: Counterattack of phages on bacterial defense (CRISPR/Cas) system.
Chaudhary K; Chattopadhyay A; Pratap D
J Cell Physiol; 2018 Jan; 233(1):57-59. PubMed ID: 28247934
[TBL] [Abstract][Full Text] [Related]
29. ErCas12a CRISPR-MAD7 for Model Generation in Human Cells, Mice, and Rats.
Liu Z; Schiel JA; Maksimova E; Strezoska Ž; Zhao G; Anderson EM; Wu Y; Warren J; Bartels A; van Brabant Smith A; Lowe CE; Forbes KP
CRISPR J; 2020 Apr; 3(2):97-108. PubMed ID: 32315227
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells.
Morisaka H; Yoshimi K; Okuzaki Y; Gee P; Kunihiro Y; Sonpho E; Xu H; Sasakawa N; Naito Y; Nakada S; Yamamoto T; Sano S; Hotta A; Takeda J; Mashimo T
Nat Commun; 2019 Dec; 10(1):5302. PubMed ID: 31811138
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-Act2.0: An Improved Multiplexed System for Plant Transcriptional Activation.
Malzahn A; Zhang Y; Qi Y
Methods Mol Biol; 2019; 1917():83-93. PubMed ID: 30610630
[TBL] [Abstract][Full Text] [Related]
32. Could CRISPR be the solution for gene editing's Gordian knot?
Fang H; Wang W
Cell Biol Toxicol; 2016 Dec; 32(6):465-467. PubMed ID: 27614448
[No Abstract] [Full Text] [Related]
33. The Implications of CRISPR-Cas9 Genome Editing for IR.
Perkons NR; Sheth R; Ackerman D; Chen J; Saleh K; Hunt SJ; Nadolski GJ; Shi J; Gade TP
J Vasc Interv Radiol; 2018 Sep; 29(9):1264-1267.e1. PubMed ID: 30146193
[No Abstract] [Full Text] [Related]
34. Repurposing the Native Type I-F CRISPR-Cas System in
Xu Z; Li Y; Yan A
STAR Protoc; 2020 Jun; 1(1):100039. PubMed ID: 33111087
[TBL] [Abstract][Full Text] [Related]
35. CAMERS-B: CRISPR/Cpf1 assisted multiple-genes editing and regulation system for Bacillus subtilis.
Wu Y; Liu Y; Lv X; Li J; Du G; Liu L
Biotechnol Bioeng; 2020 Jun; 117(6):1817-1825. PubMed ID: 32129468
[TBL] [Abstract][Full Text] [Related]
36. Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.
Jia N; Mo CY; Wang C; Eng ET; Marraffini LA; Patel DJ
Mol Cell; 2019 Jan; 73(2):264-277.e5. PubMed ID: 30503773
[TBL] [Abstract][Full Text] [Related]
37. RNA-Targeting CRISPR-Cas Systems and Their Applications.
Burmistrz M; Krakowski K; Krawczyk-Balska A
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
[TBL] [Abstract][Full Text] [Related]
38. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
[TBL] [Abstract][Full Text] [Related]
39. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
40. The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.
Hajizadeh Dastjerdi A; Newman A; Burgio G
BioDrugs; 2019 Oct; 33(5):503-513. PubMed ID: 31385197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
